surmount-1 trial tirzepatide non-diabetic obesity weight loss for maintenance of bodyweight reduction in people with in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled surmount-1 tirzepatide non-diabetic obesity weight

Should I force myself to eat on semaglutide

These include: Nausea the most frequently reported adverse effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst therapeutically intended, can occasionally be excessive) Abdominal discomfort or pain These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment or when the dose is increased

Schedule Your Consultation Today A consultation with our licensed medical team is the first step toward exploring personalized wellness options.

Pancreatitis rare but serious

Many users still achieve excellent weight loss at moderate doses